(Q37964703)

26 August 2017

title

Triazole antifungal agents in invasive fungal infections: a comparative review (English)

1 reference

invasive fungal infections

26 August 2017

main subject

1 reference

1

Cornelia Lass-Flörl

1 reference

26 August 2017

publication date

1 December 2011

1 reference

26 August 2017

1 reference

26 August 2017

volume

71

1 reference

26 August 2017

issue

18

1 reference

26 August 2017

page(s)

2405-2419

1 reference

https://scigraph.springernature.com/pub.10.2165/11596540-000000000-00000

26 August 2017

exact match

0 references

cites work

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Intravenous Itraconazole followed by Oral Itraconazole for the Treatment of Amphotericin-B-Refractory Invasive Pulmonary Aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Improved outcome in central nervous system aspergillosis, using voriconazole treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Current options in antifungal pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Clinical pharmacology of antifungal compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

The changing face of epidemiology of invasive fungal disease in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Therapy for fungal diseases: opportunities and priorities

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Pharmacokinetic/pharmacodynamic profile of posaconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Effect of food on the pharmacokinetics of multiple‐dose oral voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Clinical utility of antifungal pharmacokinetics and pharmacodynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Histamine H2‐receptor antagonists have no clinically significant effect on the steady‐state pharmacokinetics of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Management of drug and food interactions with azole antifungal agents in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Antifungal therapeutic drug monitoring: established and emerging indications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Disposition of posaconazole following single-dose oral administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Pharmacokinetics and pharmacodynamics of antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Torsades de Pointes ventricular tachycardia in a pediatric patient treated with fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Antimicrobial-associated QT interval prolongation: pointes of interest

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Long QTc interval and torsade de pointes caused by fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Voriconazole pharmacokinetics and pharmacodynamics in children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Voriconazole therapeutic drug monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Therapeutic drug monitoring for triazoles

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Treatment of invasive candidal infections: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Voriconazole salvage treatment of invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Combination treatment of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Pharmacoeconomics of voriconazole in the management of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

The direct cost and incidence of systemic fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596540-000000000-00000

Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system

21 January 2018

1 reference

12 December 2020

The effect of gastric Acid on the absorption of posaconazole

1 reference

12 December 2020

Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model

1 reference

12 December 2020

Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.

1 reference

12 December 2020

Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole

1 reference

12 December 2020

Itraconazole therapy in aspergillosis: study in 49 patients

1 reference

12 December 2020

Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole.

1 reference

12 December 2020

1 reference

12 December 2020

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

1 reference

12 December 2020

The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole

1 reference

12 December 2020

Fluconazole penetration into cerebrospinal fluid in humans

1 reference

12 December 2020

Epidemiology of invasive fungal infections in the mediterranean area

1 reference

12 December 2020

Inherited long QT syndrome revealed by antifungals drug-drug interaction

1 reference

12 December 2020

Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring.

1 reference

12 December 2020

10.2165/11596540-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1045362272

0 references

Fatcat ID

release_wvzs7dv7afbxlajrmc6oki6x2a

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wvzs7dv7afbxlajrmc6oki6x2a

24 November 2022

mapped directly with Wikidata item

1 reference